PureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the effect of the cancer drugs.
There’s been the usual flurry of announcements in the build-up to JP Morgan’s Annual Healthcare Conference, where pharma leaders will pitch their pipeline ideas to investors.
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas